Fears about the FDA mposing steep barriers to gene therapies for rare diseases appeared moot at an agency roundtable ...

Several hundred NIH employees signed on to a letter rebuking agency actions since the start of President Trump's second term ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...

The Trump executive order is not a pathway to a “gold standard” — it is a blueprint for politicizing science and ...

The Trump administration’s gutting of global aid is threatening to collapse a network of laboratories responsible for global ...

Companies like Sweetgreen, Daily Harvest, and Thrive Market have strong ties to MAHA leaders, including Casey and Calley ...

Budget documents released Friday provide the first clear indication of the priorities of the proposed Administration for a ...

Four members of the ACIP, which advises the CDC on vaccination policy, have had their status as special government employees ...

President Trump's 2026 budget proposes cutting NIH grants to universities, academic medical centers, and other institutions ...

RFK Jr.'s admission raises new concerns about a possible upcoming wave of reckless stem cell deregulation from this ...

Omada Health, a 14-year-old digital health company supporting chronic disease patients, has yet to generate profits.

Trump health officials signal eased FDA rules for rare disease gene therapy, but concerns linger over safety, oversight, and ...